[Factor XIII: experimental and clinical results in diabetic foot ulcer].
Several diseases show an impairment of vascular barrier function. In the past, we found out that topically applied plasmatic factor XIII distinctly reduced secretion tendency and improved granulation in venous ulcer. Increased vascular permeability is also discussed in patients with a long lasting diabetic status being a relevant cause of impaired local wound healing. Therefore, we introduced the topical application of factor XIII into the therapy of diabetic foot ulcer. After basic experimental investigations revealed that factor XIII significantly reduces endothelial permeability of cultured endothelial cells, the first clinically treated diabetic patients showed encouraging results, too.
Wozniak
G
G
Klinik für Herz- und Gefässchirurgie, Justus-Liebig-Universität Giessen.
Noll
T
T
Bott
U
U
Hehrlein
F W
FW
D000287:Administration, Topical; D000368:Aged; D000818:Animals; D002463:Cell Membrane Permeability / Q000187:drug effects; D002478:Cells, Cultured; D017719:Diabetic Foot / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D004730:Endothelium, Vascular / Q000473:pathology; D005176:Factor XIII / Q000008:administration & dosage* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012709:Serum Albumin / Q000378:metabolism; D013552:Swine; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
D012709:Serum Albumin; D005176:Factor XIII
Faktor XIII: experimentelle und klinische Ergebnisse beim diabetischen Malum perforans.